Embla Medical Hf S/Adr (OSSUY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

At this time, I would like to welcome everyone to this emblematical Q1 2025 conference call. Today's call is being recorded. If you have any objections, please disconnect at this time. All participants will be on listen-only mode throughout the presentation, and afterwards there will be a question and answer session. I would now like to introduce CEO Sven Silversen. Sven, over to you. Thank you very much, and good morning, and welcome to the Ampla Medical conference call where we will review the first quarter for 2025. I'm Sveit Solvason, President and CEO of Ampla Medical, and joining me on today's call is our Chief Financial Officer, Artmar Svensdottir, and Ampla Medical's Head of Investor Relations, Klaus Sindahl. The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions during a Q&A session. If you now go to the next slide, please. We are off to a reasonably good start here in 2025. Sales in the first quarter amounted to 203 million, and organic growth came in at 4%, where we had a particularly good few weeks at the end of the quarter. Growth was strong in our prosthetics and neuro-orthotics segment, supported by, I would say, continuous good momentum and solid volume growth in EMEA and APAC regions, while year started out on a softer note in the Americas following a strong end to quarter four of last year. Our EBITDA margin for the quarter came in at 18%, one percentage point above the same period last year. The stronger margin was driven by the positive effects from the cost reduction initiatives implemented in manufacturing one year ago, in quarter one last year, as well as a positive contribution from product mix and continued cost control. We're pleased to welcome Andre Rothka-Temple-Merkel as our new Ex...